Influenza roadmap:
Vaccines
Roadmap for the development of candidate vaccines for influenza
Download Influenza-vaccine-development-roadmap7
Vectored vaccines
Vectored vaccines
Research Question
- Safe vectored vaccines
Research Gaps and Challenges
- Issues with environmental release and GMO
- Identity of suitable vector
- Anti-vector responses if reused
- Current vaccines are mostly directed to a single antigen (HA)
- Lack of streamlined regulations for live vectored vaccines proven safe (e.g HVT, FPV)
- Increased cost to license is limiting the updates of vaccines
- Potential spill over into non-targeted species
- Mass administration (some practical, some are not)
Solution Routes
- Intensify research focused on novel viral vectors that provide robust immune response, drastic reduction of shedding and can be mass administered in the field
- Flexibility on vector choice to avoid anti-vector responses if reused: for
instance, one for prime, a different one for boost - New technologies and improvement of current vectored vaccines
Dependencies
- Identity of protective antigens and their genetic code – multiple antigens needed
- Identity of suitable vectors
- Safety for live vectored vaccines platforms
- Better understanding of balanced immune responses would lead to vaccines with additional viral antigen components
State Of the Art
- Mixture of two or more separate rHVT as mixture expressing different antigens do not equally work together
Projects
What activities are planned or underway?
US-UK Collab: Avian influenza virus in cattle, a framework for forecasting transmission dynamics of zoonotic disease in livestock systems
Planned Completion date 31/01/2030
Source Countries:
United States
PARTNERSHIP:Harnessing Bovine Organoids to Advance HPAI Influenza A Virus Research
Planned Completion date 14/03/2029
Source Countries:
United States